It has been recently demonstrated that high pre-treatment levels of miR-29b positively correlated with the response of patients with acute myeloid leukaemia (AML) to hypomethylating agents. Upmodulation of miR-29b by restoring its transcriptional machinery appears indeed a tool to improve therapeutic response in AML. In cells from acute promyelocytic leukaemia (APL), miR-29b is regulated by PU.1, in turn upmodulated by agonists currently used to treat APL. We explored here the ability of PU.1 to also regulate miR-29b in non-APL cells, in order to identify agonists that, upmodulating PU.1 may be beneficial in hypomethylating agents-based therapies.
down-regulated in AML and whose restoration into AML cell lines or primary samples led to a dramatic reduction of tumorigenicity. [5] [6] [7] High pre-treatments levels of miR-29b have been recently associated with longer survival in AML patients treated with conventional chemotherapy and to improved clinical response to DNA methyltransferases (DNMT) inhibitors, 8, 9 suggesting that strategies aimed to increase this miRNA may be useful in therapeutic DNA hypomethylation of leukaemic blasts. As downmodulation of miR29b correlates with different pathologies, a number of delivery systems for exogenous miR-29b have been generated. [10] [11] [12] [13] Concerning AML, a transferrin-conjugated nanoparticle method was developed to increase miR-29b in AML blasts. 14 However, despite its efficacy in in vivo AML models, this approach is not clinically available at present and activation of transcriptional expression may constitute an efficient therapeutic strategy for restoring the miR-29b level in myeloid leukaemia.
The precursors of the miR-29 family are transcribed in 2 clusters:
a miR-29a/b1 cluster located on chromosome 7 (7q32) and a miR29b2/c cluster located on chromosome 1 (1q32). The 2 distinct precursor sequences encoding for miR-29b lead to identical mature products. 10 Different binding sites for several transcriptional factors have been identified in the promoter of miR-29a/b1 and miR-29b2/ c clusters in different tissues. 5 In myeloid leukaemia cells, CEBPa was reported to only regulate the miR-29a/b1 cluster, providing the rationale for miR-29b suppression in AML patients with loss of chromosome 7q or deficiency of this transcription factor. 15 The miR29b2/c locus was shown to be activated at transcriptional level by the master myeloid regulator PU.1 in cells from acute promyelocytic leukaemia (APL) treated with all-trans-retinoic acid (ATRA). 16 PU.1 is generally deregulated in AML by mechanisms including interference with binding sites (including at its own promoter site) by PML-RARA 17 or disruption of PU.1 transactivation activity by RUNX1-ETO (AML1-ETO). 18 Even if a number of differentiating agonists may restore the levels of PU.1 in AML-derived cells, 19, 20 at present, only APL patients are treated and take advantage by the use of differentiating therapies. 1, 2 A crucial element of PU.1 transcriptional activity results from its ability to interact with a number of different protein partners, whose identification may provide the starting point for the development of targeted therapies for the treatment of haematological malignancies. 21 In APL-derived cells treated with ATRA, the interaction of PU.1 with its recognition sites on the CD11b 22 and miR-142-3p 23 promoters is entirely dependent from adequate amount of Vav1, a multidomain protein involved at different levels in agonist-induced differentiation of APL-derived promyelocytes. 24 In addition, Vav1 may regulate protein expression of ATRA-treated APL-derived cells by determining the nuclear amount of proteins implicated in mRNA production and stability. 25 This work was first aimed to assess the role of PU.1 in regulating the expression of miR-29b in non-APL cells, in order to identify agonists that, through upmodulation of this transcription factor, could be beneficial in DNA hypomethylation-based therapies. We used | 3151
an Axiovert 220M confocal microscope equipped with a 1009 oil immersion Plan-Neofluar objective (NA 1.3, from Carl Zeiss, G€ ottingen, Germany) and a CoolSnap HQ CCD camera. On the basis of the described PU.1-mediated expression of miR-29b induced by ATRA in NB4 cells, 16 this agonist was first administered to Kasumi-1. As expected, 29 ATRA induced a slight cell adhesion ( Figure S1A ), indicative of a partial differentiation along the monocyte-macrophage lineage, and a substantial increase in PU.1
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( Figure 1A ,B). Nevertheless, unlike what was observed in NB4 cells, 16 ATRA failed to significantly upmodulates the miR-29b levels in Kasumi-1 ( Figure 1C , Figure S1B ).
We then treated Kasumi-1 with PMA, known to activate PU.1 in myeloid cells. 30 We found that PU.1 expression increased in treated conditions ( Figure 1A For this purpose, ChIP assay was performed using specific primers that amplify the potential PU.1 binding sites in the 5 0 regulatory regions ( Figure 2A ). As shown in Figure 2B , PU.1 was selectively recruited to the miR-29b locus on chromosome 7 also in control conditions and PMA, but not ATRA, led to a significant increase in DNA associated with the transcription factor. A region of DNA flanking the miR-29b
promoter on Chr 7 and not predicted to bind PU.1 was also used in the ChIP assays, confirming the specific in vivo recruitment of this transcription factor in both control and PMA-treated Kasumi-1 ( Figure S2 
